Global Oligonucleotide Therapeutics Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 92

Report ID: 1381

Oligonucleotides are short nucleotides sequences of DNA or RNA molecules called oligomers. Oligonucleotide therapeutics target and inhibit the expression of certain diseases-causing genes, thus forming a new class of therapeutics to treat chronic diseases.
In terms of geographic regions, the North Americas accounted for the major share in the antisense oligonucleotides market in 2017. The major reason for the market growth in this region is due to the increasing approval of products.
In 2018, the global Oligonucleotide Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Oligonucleotide Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Oligonucleotide Therapeutics development in United States, Europe and China.

The key players covered in this study
Arrowhead Pharmaceuticals
GlaxoSmithKline
Ionis Pharmaceuticals
miRagen Therapeutics
Sarepta Therapeutics
...

Market segment by Type, the product can be split into
Antisense/RNAi oligonucleotides
Others

Market segment by Application, split into
Neurological disorders
Cancer
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Oligonucleotide Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Oligonucleotide Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Oligonucleotide Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Oligonucleotide Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Antisense/RNAi oligonucleotides
1.4.3 Others
1.5 Market by Application
1.5.1 Global Oligonucleotide Therapeutics Market Share by Application (2014-2025)
1.5.2 Neurological disorders
1.5.3 Cancer
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Oligonucleotide Therapeutics Market Size
2.2 Oligonucleotide Therapeutics Growth Trends by Regions
2.2.1 Oligonucleotide Therapeutics Market Size by Regions (2014-2025)
2.2.2 Oligonucleotide Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Oligonucleotide Therapeutics Market Size by Manufacturers
3.1.1 Global Oligonucleotide Therapeutics Revenue by Manufacturers (2014-2019)
3.1.2 Global Oligonucleotide Therapeutics Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Oligonucleotide Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Oligonucleotide Therapeutics Key Players Head office and Area Served
3.3 Key Players Oligonucleotide Therapeutics Product/Solution/Service
3.4 Date of Enter into Oligonucleotide Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Oligonucleotide Therapeutics Market Size by Type (2014-2019)
4.2 Global Oligonucleotide Therapeutics Market Size by Application (2014-2019)

5 United States
5.1 United States Oligonucleotide Therapeutics Market Size (2014-2019)
5.2 Oligonucleotide Therapeutics Key Players in United States
5.3 United States Oligonucleotide Therapeutics Market Size by Type
5.4 United States Oligonucleotide Therapeutics Market Size by Application

6 Europe
6.1 Europe Oligonucleotide Therapeutics Market Size (2014-2019)
6.2 Oligonucleotide Therapeutics Key Players in Europe
6.3 Europe Oligonucleotide Therapeutics Market Size by Type
6.4 Europe Oligonucleotide Therapeutics Market Size by Application

7 China
7.1 China Oligonucleotide Therapeutics Market Size (2014-2019)
7.2 Oligonucleotide Therapeutics Key Players in China
7.3 China Oligonucleotide Therapeutics Market Size by Type
7.4 China Oligonucleotide Therapeutics Market Size by Application

8 Japan
8.1 Japan Oligonucleotide Therapeutics Market Size (2014-2019)
8.2 Oligonucleotide Therapeutics Key Players in Japan
8.3 Japan Oligonucleotide Therapeutics Market Size by Type
8.4 Japan Oligonucleotide Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Oligonucleotide Therapeutics Market Size (2014-2019)
9.2 Oligonucleotide Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Oligonucleotide Therapeutics Market Size by Type
9.4 Southeast Asia Oligonucleotide Therapeutics Market Size by Application

10 India
10.1 India Oligonucleotide Therapeutics Market Size (2014-2019)
10.2 Oligonucleotide Therapeutics Key Players in India
10.3 India Oligonucleotide Therapeutics Market Size by Type
10.4 India Oligonucleotide Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Oligonucleotide Therapeutics Market Size (2014-2019)
11.2 Oligonucleotide Therapeutics Key Players in Central & South America
11.3 Central & South America Oligonucleotide Therapeutics Market Size by Type
11.4 Central & South America Oligonucleotide Therapeutics Market Size by Application

12 International Players Profiles
12.1 Arrowhead Pharmaceuticals
12.1.1 Arrowhead Pharmaceuticals Company Details
12.1.2 Company Description and Business Overview
12.1.3 Oligonucleotide Therapeutics Introduction
12.1.4 Arrowhead Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2014-2019)
12.1.5 Arrowhead Pharmaceuticals Recent Development
12.2 GlaxoSmithKline
12.2.1 GlaxoSmithKline Company Details
12.2.2 Company Description and Business Overview
12.2.3 Oligonucleotide Therapeutics Introduction
12.2.4 GlaxoSmithKline Revenue in Oligonucleotide Therapeutics Business (2014-2019)
12.2.5 GlaxoSmithKline Recent Development
12.3 Ionis Pharmaceuticals
12.3.1 Ionis Pharmaceuticals Company Details
12.3.2 Company Description and Business Overview
12.3.3 Oligonucleotide Therapeutics Introduction
12.3.4 Ionis Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2014-2019)
12.3.5 Ionis Pharmaceuticals Recent Development
12.4 miRagen Therapeutics
12.4.1 miRagen Therapeutics Company Details
12.4.2 Company Description and Business Overview
12.4.3 Oligonucleotide Therapeutics Introduction
12.4.4 miRagen Therapeutics Revenue in Oligonucleotide Therapeutics Business (2014-2019)
12.4.5 miRagen Therapeutics Recent Development
12.5 Sarepta Therapeutics
12.5.1 Sarepta Therapeutics Company Details
12.5.2 Company Description and Business Overview
12.5.3 Oligonucleotide Therapeutics Introduction
12.5.4 Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2014-2019)
12.5.5 Sarepta Therapeutics Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details